Lates News

On February 10th, China's Class 1 innovative drug - Benazepril Maleate Tablets (trade name "Xintuoan") was prescribed for the first time at the Pudong New Area Gongli Hospital in Shanghai. This new generation of direct renin inhibitor, developed and produced by Shanghai Pharmaceuticals Group Co., Ltd., has been successfully put into clinical use, not only bringing a new treatment option for patients with primary hypertension but also marking a significant achievement in the research and production of innovative drugs in the relevant treatment field in China. This is also one of the important achievements in the innovative development of the biopharmaceutical industry in Shanghai. (e Company).